Trevi Therapeutics Inc (TRVI) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Cash and Cash Equivalents: Approximately $188 million at the end of 2025. Cash Runway: Expected to extend into 2028. Release Date: March 17, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Trevi Therapeutics Inc ( NASDAQ:TRVI ) reported positive data readouts from the CORAL and RIVER trials, which have driven growth and capital raising. The company had a successful end of Phase II meeting with the FDA for its IPF-related chronic cough program, gaining alignment on the path to NDA. Trevi Therapeutics Inc ( NASDAQ:TRVI ) plans to initiate two pivotal Phase III clinical trials for IPF-related chronic cough, with clear timelines and trial designs. The company has a strong cash position with $188 million, providing a runway into 2028 to support key clinical milestones. Trevi Therapeutics Inc ( NASDAQ:TRVI ) is expanding its clinical footprint into the U.S.
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics (TRVI) had its price target lowered by JonesTrading from $25.00 to $24.00. They now have a "buy" rating on the stock.MarketBeat
- Trevi Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Trevi Therapeutics (TRVI) had its price target lowered by Morgan Stanley from $19.00 to $18.00. They now have an "overweight" rating on the stock.MarketBeat
- Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $19.00 price target on the stock.MarketBeat
- Trevi Therapeutics (TRVI) had its price target raised by Needham & Company LLC from $22.00 to $24.00. They now have a "buy" rating on the stock.MarketBeat
TRVI
Earnings
- 3/17/26 - Beat
TRVI
Sec Filings
- 3/17/26 - Form 10-K
- 3/17/26 - Form 8-K
- 3/9/26 - Form 8-K
- TRVI's page on the SEC website